IMM Immupharma Plc

 

TIDMIMM 
 
RNS Number : 1612M 
Immupharma PLC 
19 May 2010 
 

FOR IMMEDIATE RELEASE 
 
          19 May 2010 
 
                        IMMUPHARMA RECEIVES APPROVAL FOR 
               INITIATION OF PHASE I/IIA STUDIES IN CANCER 
 
 
 
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug 
discovery and development company, is pleased to announce that it received an 
Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de 
Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of 
 IPP-204106, its anti-cancer compound with a novel and promising mechanism of 
action.  The first patients are expected to be dosed within the next few weeks. 
 
 
Dr Robert Zimmer, President and Chief Scientific Officer, said:  "We are 
delighted with the approval of our IND application, and are excited to begin 
Phase I in patients for IPP-204106 in the next few weeks.  Importantly, our 
strong financial position means we are well-placed to take the development 
programme forward." 
 
 
For further information please contact: 
 
ImmuPharma PLC 
Robert Zimmer, President & Chief Scientific Officer                      +33 3 
8932 7650 
Richard Warr, Chairman 
         +44 20 7152 4080 
 Dimitri Dimitriou, Chief Executive Officer 
                              +44 20 7152 4080 
 
 
Buchanan Communications 
 + 44 20 7466 5000 
Lisa Baderoon 
 Catherine Breen 
George Prassas 
 
Panmure Gordon & Co 
      +44 151 243 0963 
Andrew Burnett 
Rakesh Sharma 
 
Execution Noble & Co 
James Bromhead 
             +44 20 7456 9191 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCMMGMKMRLGGZZ 
 

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024